Ning Feng, Ye Jin, Wei Li-Qiang, Li Xin, Wang Jing-Wen
Department of Hematology, Capital University of Medical Sciences, Beijing, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Aug;20(4):912-6.
The aim of this study was to analyze the efficacy of first-line chemotherapy in treating patients with ocular adnexal extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT). Eight consecutive newly diagnosed ocular adnexal MALT lymphoma patients were treated with chemotherapy, in which 3 patients in stage IE were treated with a combination of cyclophosphamide, vincristine and prednisolone (COP) or cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP), 5 patients in stage IV were treated with COP/CHOP in combination with rituximab. The results showed that chemotherapy resulted in an overall response rate of 100%, 3 patients in stage IE were in partial remission (PR), 5 patients in stage IV were in complete remission (CR). After a median follow-up of 21 months, 3 patients in stage IE were still in PR status, 5 patients in stage IV were still in CR status, and no relapses or disease progression were observed. It is concluded that the first-line chemotherapy has been confirmed to be effective and well tolerated in patients with localized ocular adnexal MALT lymphoma. Rituximab combined with chemotherapy can increase remission rate, it is feasible option as first-line treatment for ocular adnexal MALT lymphoma.
本研究旨在分析一线化疗治疗黏膜相关淋巴组织（MALT）眼附属器结外边缘区B细胞淋巴瘤患者的疗效。连续8例新诊断的眼附属器MALT淋巴瘤患者接受化疗，其中3例IE期患者接受环磷酰胺、长春新碱和泼尼松（COP）或环磷酰胺、阿霉素、长春新碱和泼尼松（CHOP）联合治疗，5例IV期患者接受COP/CHOP联合利妥昔单抗治疗。结果显示，化疗的总缓解率为100%，3例IE期患者部分缓解（PR），5例IV期患者完全缓解（CR）。中位随访21个月后，3例IE期患者仍处于PR状态，5例IV期患者仍处于CR状态，未观察到复发或疾病进展。结论是，一线化疗已被证实对局限性眼附属器MALT淋巴瘤患者有效且耐受性良好。利妥昔单抗联合化疗可提高缓解率，是眼附属器MALT淋巴瘤一线治疗的可行选择。
